Brain stimulation for arm recovery after stroke (B-STARS): protocol for a randomised controlled trial in subacute stroke patients

Eline C C van Lieshout,1 Johanna M A Visser-Meily,2 Sebastiaan F W Neggers,3 H Bart van der Worp,4 Rick M Dijkhuizen1

ABSTRACT

Introduction Many patients with stroke have moderate to severe long-term sensorimotor impairments, often including inability to execute movements of the affected arm or hand. Limited recovery from stroke may be partly caused by imbalanced interaction between the cerebral hemispheres, with reduced excitability of the ipsilesional motor cortex while excitability of the contralesional motor cortex is increased. Non-invasive brain stimulation with inhibitory repetitive transcranial magnetic stimulation (rTMS) of the contralesional hemisphere may aid in relieving a post-stroke interhemispheric excitability imbalance, which could improve functional recovery. There are encouraging effects of theta burst stimulation (TBS), a form of TMS, in patients with chronic stroke, but evidence on efficacy and long-term effects on arm function of contralesional TBS in patients with subacute hemiparetic stroke is lacking.

Methods and analysis In a randomised clinical trial, we will assign 60 patients with a first-ever ischaemic stroke in the previous 7–14 days and a persistent paresis of one arm to 10 sessions of real stimulation with TBS of the contralesional primary motor cortex or to sham stimulation over a period of 2 weeks. Both types of stimulation will be followed by upper limb training. A subset of patients will undergo five MRI sessions to assess post-stroke brain reorganisation. The primary outcome measure will be the upper limb function score, assessed from grasp, grip, pinch and gross movements in the action research arm test, measured at 3 months after stroke. Patients will be blinded to treatment allocation. The primary outcome at 3 months will also be assessed in a blinded fashion.

Ethics and dissemination The study has been approved by the Medical Research Ethics Committee of the University Medical Center Utrecht, The Netherlands. The results will be disseminated through (open access) peer-reviewed publications, networks of scientists, professionals and the public, and presented at conferences.

Trial registration number NTR6133

Strengths and limitations of this study

► To the best of our knowledge, this is one of the first clinical trials evaluating the effect of theta burst stimulation on motor function in patients with subacute stroke (within 2 weeks).
► Long-term follow-up period up to 1 year after stroke onset, enabling assessment of durability of treatment effects.
► Multiple, different outcome measures, including motor function, activities of daily living and neural network activity.
► Participants are blinded to their allocated treatment group throughout the trial, but study personnel is only blinded for the primary outcome measurement at 3 months.

INTRODUCTION

Each year >15 million people worldwide have a stroke, which is a major cause of adult disability. The most common functional deficits after stroke are sensorimotor impairments, which, in addition to functional disability, can have considerable negative effects on quality of life and societal participation.1–3 In 33%–66% of stroke patients with a paretic arm, recovery of arm function is absent or negligible in the first 6 months,6–8 and >50% do not show signs of significant arm function recovery after >5 years post-stroke.9–12

On the other hand, 5%–20% of patients with impaired arm function after stroke demonstrate full functional recovery of arm function within 6 months.6,11 Rehabilitation programs contribute to functional recovery, and significant improvements in sensorimotor function can be achieved.7,14 Several studies suggest that functional improvement after stroke may be augmented by strategies that involve neuromodulation through non-invasive brain stimulation, such as TMS, in combination with rehabilitative training.15–21

TMS provides a non-invasive and safe way to directly facilitate or suppress brain activity in cortical areas. TMS induces a current in the cerebral cortex through a coil that generates
a magnetic field. Repetitive delivery of TMS (rTMS) with a high-frequency train of pulses is believed to enhance cortical excitability, while repetitive low-frequency TMS would suppress cortical excitability. TMS-induced reduction of cortical excitability has been associated with long-term depression (LTD)-like effects, whereas TMS-induced increase of corticospinal excitability has been associated with long-term potentiation-like effects.

Recently, patterned protocols consisting of short trains of high-frequency TMS (30–100 Hz) alternating with rest periods in the theta frequency range (4–7 Hz) (theta burst stimulation (TBS)) have been reported to provide effective and reliable paradigms for an excitatory (intermittent TBS (iTBS)) or inhibitory (continuous TBS (cTBS)) brain stimulation. Three pulses of stimulation are delivered at 50 Hz, given every 200 ms. TBS paradigms are particularly promising because stimulation sessions are shorter (2–3 min or less) (ie, more practical) as compared with standard rTMS protocols (20–30 min).

Patients with hemiparetic stroke often have a functionally imbalanced interaction between the damaged and undamaged brain hemispheres, with reduced excitability of the ipsilesional motor cortex while excitability in the contralesional motor cortex is increased. Recent proof-of-principle studies have demonstrated that specific TMS paradigms—that is, facilitatory stimulation of the affected hemisphere to upregulate excitability or inhibitory stimulation of the unaffected hemisphere to downregulate excitability—can elicit significant behavioural improvement in recovering patients with stroke. cTBS of the intact contralesional primary motor cortex may offer the most straightforward approach, as this brain region is easily identified from single-pulse TMS-induced motor evoked potentials (MEPs), which is more complicated in the structurally and/or functionally injured ipsilesional motor cortex.

The feasibility and safety of TBS in patients with hemiparetic stroke have been demonstrated in a number of studies. However, most earlier studies involved chronic stroke patients in whom post-stroke neural network reorganisation had probably stabilised already, which may constrain the therapeutic potential of TBS. The most recent of these studies was a randomised controlled trial (RCT) in which chronic subcortical stroke patients were treated with iTBS of the ipsilesional motor cortex directly followed by upper limb physical therapy, daily for 10 days. Upper limb function, assessed with the action research arm test (ARAT), improved for at least 1 month after treatment compared with sham therapy. Until now, however, a RCT on the long-term effects of TBS treatment in patients with subacute hemiparetic stroke is lacking. Previous studies that tested TMS treatment in the subacute phase after stroke applied low-frequency or high-frequency rTMS, some had a small sample size (18–58 patients) or was not supported by a power calculation and relatively short intervention duration of 5–10 days. A RCT on the long-term effects of repetitive TBS in a larger patient population subacutely after stroke would provide important new insights into the therapeutic efficacy of this non-invasive and practicable intervention during an optimal time window for neurorehabilitation, especially in combination with a pragmatic upper limb training approach directly following brain stimulation.

Objectives
The primary objective of this study is to determine the therapeutic effect of contralesional cTBS (inhibitory stimulation) on recovery of function of the paretic arm at 3 months after ischaemic stroke. The secondary objectives are to evaluate:

1. the mode of action of contralesional cTBS on neural network reorganisation after ischaemic stroke, at different time points;
2. the therapeutic effect of contralesional cTBS on other sensorimotor functions, at different time points post-treatment and
3. the therapeutic effect of contralesional cTBS on disability and quality of life, at different time points post-treatment.

METHODS AND ANALYSIS
Study design
The Brain-STimulation for Arm Recovery after Stroke study is a prospective, randomised, double-blind, controlled clinical trial. Subjects will be randomly allocated to real or sham brain stimulation, followed by standard care upper limb training. They will remain blinded to treatment allocation. Non-invasive brain stimulation will involve 10 daily sessions of cTBS of the contralesional hand area of the primary motor cortex over a period of 2 weeks. The first cTBS session will be executed within 2 weeks after stroke onset. Patients will be tested seven times in total (figure 1): at the start of the study (T0; baseline), at the 10th day of the intervention (T1), at 1 week (T2) and 1 month (T3) after stimulation, and at 3 months (T4), 6 months (T5) and 1 year after stroke onset (T6). All baseline and follow-up assessments, except for the primary outcome measurement, will be conducted by a trained researcher (ECCvL) with support from research assistants.

The study has been approved by the Medical Research Ethics Committee of the University Medical Center Utrecht.

We used the Standard Protocol Items: Recommendations for Interventional Trials recommendations on reporting.

Study population
Participants (total of 60) will be recruited from the University Medical Center Utrecht and rehabilitation centre De Hoogstraat in Utrecht, The Netherlands. Patients who fulfill the study criteria will be asked to participate, and they will receive a patient information letter explaining the background and methods of the study. Patients can decide to participate with...
Figure 1  Schematic overview of the study procedure. TMS, transcranial magnetic stimulation.

or without additional MRI scanning at the University Medical Center Utrecht. After giving written informed consent, patients will be randomly allocated to the treatment procedures.

Inclusion and exclusion criteria
The inclusion criteria of this study are: (1) patient age ≥18 years; (2) first-ever unilateral ischaemic stroke; (3) paresis of one arm, with Shoulder Abduction and Finger Extension scores for shoulder abduction of ≥9 on the Motricity Index and for finger extension of ≥1 on the Fugl-Meyer score\(^5\); (4) admission to ‘De Hoogstraat’ within the first 2 weeks after stroke onset and (5) written informed consent. The exclusion criteria are: (1) disabling medical history (severe or recent heart disease, severe head trauma and coercively treated at a psychiatric ward); (2) history of epilepsy; (3) normal to almost
normal use of hand, with a Motricity Index hand score of 33 (maximum score for this item, reflecting ‘normal’ function); (4) severe deficits in communication, memory or understanding that impede proper study participation, as determined by the treating physician and (5) contraindications for TMS (metal (implants) in skull/scalp/head or fragments from welding or metalwork, implanted device (eg, spinal cord stimulator, cardiac pacemaker and cochlear implants), pregnancy and so on).  

Randomisation
Patients will be randomly assigned to either the real cTBS or sham cTBS group, stratified to the severity of their arm paresis. Patients in the high-performance group must demonstrate a minimal ability of finger extension of the thumb or one or more fingers, while patients in the low-performance group have no ability of finger extension of the thumb or one or more fingers. Randomisation will be performed with a secured electronic data capture system (Research Online V.2.0, Julius Centrum). This will be done after the baseline assessment to account for possible improvements in motor function during the first days after stroke.

Intervention
All patients will receive the current standard rehabilitation programme parallel to the treatment. The rehabilitation programme consists of daily group treatment focused on the arm/hand (on functional and activity level, ca. 60 min), next to individual physical therapy, occupational therapy, creative therapy, speech therapy and so on. All therapists and other rehabilitation staff will be blinded to group allocation. In addition, real cTBS or sham cTBS in combination with upper limb training will be performed in daily sessions during 2 weeks (10 working days), starting within 7–14 days after stroke onset. TBS will be performed using a Neuro-MS/D Advanced Therapeutic stimulator (Neurosoft, Russia). cTBS will only be executed at rehabilitation centre De Hoogstraat. We will employ a standard cTBS paradigm consisting of three stimuli bursts at 50 Hz, repeated at 5 Hz frequency, resulting in 600 stimuli in 40 s. cTBS intensity will be at 70% of resting motor threshold (RMT), which induces highly consistent LTD-like MEP suppression with low intersubject variability. Sham stimulation will be done with the stimulator in the sham mode (generates pulses at 90% lower intensity of RMT), with the coil oriented at an angle of 45° relative to the scalp. For each session, the RMT will be determined from electromyography (EMG) (recorded with two Ag/AgCl surface electrodes) from the contralateral first dorsal interosseous (FDI) muscle. The motor threshold will be defined as the minimum intensity of TMS over the hand area of the contralesional primary motor cortex to elicit at least five contralateral MEPs with >50 μV peak-to-peak amplitude in 10 trials with 7 s intertrial intervals. A neuronavigation system (Brain Science Tools, the Netherlands), using a prestimulation CT or MRI scan (both techniques have been successfully applied for stereotactic imaging55 56) will be used to ensure consistent coil placement for cTBS of the hand area of the primary motor cortex. Applied protocol(s) will be in accordance with most recent safety and tolerability guidelines for TMS applications.27 57 58

Outcome measures
Primary outcome measure
The primary outcome measure will be the change in the modified ARAT score59 assessed at 3 months post-stroke (see table 1 for all times of testing). The ARAT is a performance test which assesses the ability to perform gross movements and the ability to grasp, move and release objects differing in size, weight and shape. The original test consists of 19 items, rated on 4-point ordinal scales (0–3), with a maximum score of 57 (best performance). By removing four items, a hierarchical one-dimensional

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Overview of functional outcome measures (motor function tests and questionnaires, including timing)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Instruments</strong></td>
<td><strong>T0</strong></td>
</tr>
<tr>
<td>Motor function</td>
<td></td>
</tr>
<tr>
<td>ARAT (primary outcome measure)</td>
<td>X</td>
</tr>
<tr>
<td>FM</td>
<td>X</td>
</tr>
<tr>
<td>SULCS</td>
<td>X</td>
</tr>
<tr>
<td>9HPT</td>
<td>X</td>
</tr>
<tr>
<td>JTT</td>
<td>X</td>
</tr>
<tr>
<td>Societal participation</td>
<td></td>
</tr>
<tr>
<td>SIS (hand function subscale + ‘thermometer’ of well-being)</td>
<td>X</td>
</tr>
<tr>
<td>Modified Rankin Scale</td>
<td>X</td>
</tr>
<tr>
<td>HADS</td>
<td>X</td>
</tr>
</tbody>
</table>

The first assessment (T0) takes place in the first 7–14 days post-stroke. The follow-up assessments are at the last day of the stimulation session (T1): at 1 week (T2), 1 month (T3) after stimulation; and 3 months (T4), 6 months (T5) and 1 year (T6) post-stroke. ARAT, action research arm test; FM, Fugl-Meyer score test; HADS, Hospital Anxiety and Depression Scale; JTT, Jebsen-Taylor Test; 9HPT, Nine-hole Peg Test; SIS, Stroke Impact Scale; SULCS, Stroke Upper Limb Capacity Scale.
scale has been constructed. The ARAT has shown good psychometric properties in patients with stroke with mild to moderate motor severity and without severe cognitive impairment. It has also evidence of unidimensionality, predictive validity and reliability. The ARAT at 3 months will be performed by an independent assessor who will be blinded to treatment allocation.

Secondary outcome measures

In addition to the ARAT score, we will measure sensorimotor function with the following tests: Fugl-Meyer score test, Nine-Hole Peg Test, Jebsen-Taylor hand test and the Stroke Upper Limb Capacity Scale (SULCS) test. The Fugl-Meyer arm score test is a reliable and valid motor performance test consisting of 33 tasks executed with the affected upper limb. Performance on each task is rated as 0, 1 or 2, with higher ratings representing better performance. The Nine-Hole Peg Test examines the speed of movement of fine motor skills. The duration of the task execution will be measured. The maximum allowed time will be 50 s, during which the number of pegs is counted. The Nine-Hole Peg Test has demonstrated good reliability and validity and has the ability to be used across the age span. Hand skill will be measured with the Jebsen-Taylor hand test. The scores on all seven items, representing activities during daily living, will be summed for a total score. The Jebsen-Taylor test is a reliable and valid measure of gross functional dexterity. The SULCS assesses arm function capacity, and basal and complex hand function capacity. It consists of 10 items, each of which is scored with 0 or 1. The SULCS has shown good psychometric properties and assesses upper limb capacity according to the International Classification of Functioning, Disability and Health definition.

The following outcome measurements will be used to measure dependency, quality of life and depression: modified Rankin Scale, Stroke Impact Scale and Hospital Anxiety and Depression Scale. The modified Rankin Scale assesses disability and is subdivided into six scores. Score ‘0’ corresponds to no symptoms, whereas score ‘5’ corresponds to severe handicap. When adhering to a series of rules and a structured interview, the modified Rankin Scale proved to be a reliable and valid measure. The Stroke Impact Scale is a self-report health status measure, specifically developed for the stroke population. This multidimensional instrument measures hand function, strength, activities of daily living, communication, emotion, memory and thinking. The Stroke Impact Scale has shown good psychometric properties in a diverse group of stroke survivors. The Hospital Anxiety and Depression Scale measures the core symptoms of anxiety and depression without involving physical symptoms. This scale is commonly used in patients with stroke and has good psychometric properties.

Corticospinal excitability and intracortical inhibition will be assessed from the amplitude and latency of MEP responses, respectively, induced by single-pulse TMS to the ipsilesional and contralesional primary motor cortex, measured by EMG with surface electrodes over the FDI muscle of both hands. Stimulus-response curves will be measured from 12 MEP recordings at 95%, 105%, 115%, 125% and 135% stimulus intensity relative to the RMT (in random order).

To assess patients’ functional brain status, we will measure functional MRI (fMRI)-based sensorimotor activation (eg, percentage of blood oxygen-level dependent change) and resting-state fMRI-based functional connectivity in ipsilesional and contralesional sensory and motor regions. In addition, we will apply diffusion tensor imaging to assess structural integrity of the bilateral corticospinal tract and other white matter areas, based on different diffusion parameters (eg, fractional anisotropy). fMRI will be executed on a clinical 3T scanner. Task-related fMRI will be done during flexion–extension movement of the fingers of the hand in a blocked design. Before MRI scanning, patients will be trained to perform the task correctly. The secondary outcome measures including moment of administering can be found in tables 1 and 2.

Other baseline data and parameters

The following parameters will be screened from the medical records of patients and from questionnaires to control for possible confounding effects (see table 3 for an overview and the timing):

1. Use of alcohol or drugs in previous 12 hours, use of caffeine in previous 2 hours and quality of last night’s sleep prior to brain stimulation
2. Complaints of dizziness, headache, insult, tiredness, muscle stiffness and so on after brain stimulation
3. Medication (that lowers the seizure threshold)
4. Amount of (physical) therapy and self-practice

<table>
<thead>
<tr>
<th>Brain status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corticospinal excitability and intracortical inhibition</td>
</tr>
<tr>
<td>Ischaemic injury, white matter integrity, functional connectivity and cortical activation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Instrument</th>
<th>T0</th>
<th>T1</th>
<th>T2</th>
<th>T3</th>
<th>T4</th>
<th>T5</th>
<th>T6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnostic TMS</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>(f)MRI (optional)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

The first assessment (T0) takes place in the first 7–14 days post-stroke. The follow-up assessments are at the last day of the stimulation session (T1); at 1 week (T2), 1 month (T3) after stimulation; and 3 months (T4), 6 months (T5) and 1 year (T6) post-stroke. fMRI, functional MRI; TMS, transcranial magnetic stimulation.
Table 3 Overview of measures that are part of care as usual and extra care

<table>
<thead>
<tr>
<th>Instrument</th>
<th>T0</th>
<th>Treatment</th>
<th>T1</th>
<th>T2</th>
<th>T3</th>
<th>T4</th>
<th>T5</th>
<th>T6</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Activities of daily living</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barthel Index</td>
<td>X</td>
<td>X*</td>
<td>X*</td>
<td>X*</td>
<td>X*</td>
<td>X*</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Demographics and stroke characteristics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, gender, education, marital status, ethnicity, work status and handedness</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MOCA</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type of stroke, stroke severity (NIHSS) and side affected limb</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other parameters</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Use of alcohol/caffeine/drugs, medication, (physical) therapy/self-practice and poststimulation complaints</td>
<td>X*</td>
<td>X*</td>
<td>X*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The first assessment (T0) takes place in the first 7–14 days post-stroke. The follow-up assessments are at the last day of the stimulation session (T1), and at 1 week (T2), 1 month (T3) after stimulation, 3 months (T4), 6 months (T5) and 1 year (T6) post-stroke. MOCA, Montreal Cognitive Assessment; NIHSS, National Institutes of Health Stroke Scale. *, extra care.

5. Demographic parameters at baseline: gender, age, education level, handedness, marital status and ethnicity

6. Stroke-related parameters at baseline: type of stroke, stroke severity (National Institutes of Health Stroke Scale), side affected limb, days since stroke onset and cognition (Montreal Cognitive Assessment).

**Data management**
Data will be collected in an electronic case report form. Data will be stored on a password-protected electronic server (OpenClinica V.2.0). This is only accessible by the researchers, according to the authorisation form. Data will be analysed on completion of the study. Participants will be given an anonymous study ID to protect confidentiality, and only investigators will have access to the final trial dataset.

**Statistics**
**Sample size**
Total sample size will be 60 patients, 30 patients per group, based on a recent meta-analysis that showed a mean effect size on motor outcome after rTMS of 0.55 with a 95% CI of 0.18 (statistical programme G*power, statistical power 80%).

**Statistical analyses**
ARAT scores will be statistically analysed using repeated measures analysis of variance (ANOVA) with ‘time’ (different time points before and after treatment) as within-subject factor and ‘treatment’ (real cTBS vs sham cTBS) as between-subject factor. Paired t-tests with correction for multiple comparisons will be used for post hoc analysis. Before entering the data in ANOVA, we will check for normal distribution with the Kolmogorov-Smirnov test. Alternatively, Wilcoxon signed-rank tests will be used to analyse ARAT scores.

Secondary outcome parameters, that is, the additional sensorimotor function measures, disability/quality of life scores and measures of corticospinal excitability and intracortical inhibition, will be analysed in the same way as described for ARAT scores.

Statistical analysis of MRI parameters will involve repeated measures ANOVA with ‘time’ (different time points before and after treatment) as within-subject factor and ‘treatment’ (real cTBS vs sham cTBS) as between-subject factor, followed by post hoc t-testing with correction for multiple comparisons. For predictive modelling, we will employ generalised linear model-based algorithms, but we may also use alternative algorithms that we have recently tested on their ability to predict infarction based on multiparametric MRI.

All patients will be included in the analyses following an intention-to-treat approach. We do not plan to perform any interim analyses.

**ETHICS AND DISSEMINATION**

**Ethics**
The study has been approved by the Medical Research Ethics Committee of the University Medical Center Utrecht.

Before inclusion, patients should have read the patient information letter, which they may discuss with their relatives, to understand the goal and execution plan of the trial. After giving written informed consent patients can participate. Before the first examination, a researcher will restate the study information, and patients will (again) be informed about the possibility to ask questions about the study. Furthermore, the option to withdraw from the study at any time will be explained. If the patient is not able to write down the needed information (because of hand/arm disability), a relative can fill out the informed consent form. The study will be conducted in accordance with the principles of Good Clinical Practice, the Medical Research Involving Human Subjects act and the Declaration of Helsinki. All protocol changes such as
modifications in eligibility criteria, outcome measures, analyses or study procedures will be submitted to the Medical Research Ethics Committee.

Safety

Adverse events are defined as any undesirable medical experience occurring to a subject during the study, whether or not considered related to cTBS. All adverse events reported spontaneously by the subject to (or observed by) the investigator or his/her staff will be recorded for the period of the treatment (2 weeks) and for an additional week after the treatment has ended. Seizures, which are the most serious rTMS-related side effect with a crude risk of approximately 0.02%, 57 would only be expected to occur during or immediately after rTMS trains. Furthermore, all adverse events occurring within 24 hours after MRI will be reported. Any serious event will be immediately reported to the Medical Research Ethics Committee of the University Medical Center Utrecht.

An internal Data Safety and Monitoring Board (DSMB) at the University Medical Center Utrecht has been established to perform ongoing safety surveillance. A temporary, independent project-specific member is added to the internal DSMB. The internal DSMB will monitor the progress (randomisation and losses to follow-up) and safety (evidence for significant treatment harm) aspects of the study. The internal DSMB may also advise on protocol modifications suggested by investigators or sponsors and assess impact and relevance of external evidence.

Dissemination

The results will be disseminated through (open access) peer-reviewed publications, networks of scientists, patient associations (like ‘Hersenletsel.nl’ and ‘Kennisnetwerk CVA NL’), professionals and the public, and presented at relevant conferences. Participants of the study will be updated about the progress and results of the study by newsletters. Patient engagement will be achieved by involving patients in the development of the protocol and script, for example, in improving and refining the motor task during fMRI.

Acknowledgements

The authors thank Wilma Jentink and Annet Stabbeekorn for their input on the protocol.

Contributors

RD conceived the study concept, RD, EVL, AV and BvdW designed the protocol. BN contributed to the conception of the protocol. EVL drafted the manuscript. All authors provided feedback throughout the development of the protocol and approved the final manuscript.

Funding

This work was supported by the Netherlands Organization for Scientific Research (VICI 016.130.662).

Competing interests

None declared.

Patient consent

Obtained.

Ethics approval

Medical Research Ethics Committee of the University Medical Center Utrecht.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data sharing statement

To promote the independent re-use of B-STARS data and to save the costs of unnecessarily compiling new datasets, access to a clean, anonymous, and well-annotated dataset will be made publicly available in a public data repository within 18 months of the final follow-up of the last patient. This will allow the B-STARS investigators sufficient time to explore the datasets, balanced by the public interest of timely access. This sharing of participant-level data will provide others the opportunity to examine new research questions and will therefore increase the impact of B-STARS.

Acknowledgements

The authors thank Wilma Jentink and Annet Stabbeekorn for their input on the protocol.

Contributors

RD conceived the study concept, RD, EVL, AV and BvdW designed the protocol. BN contributed to the conception of the protocol. EVL drafted the manuscript. All authors provided feedback throughout the development of the protocol and approved the final manuscript.

Funding

This work was supported by the Netherlands Organization for Scientific Research (VICI 016.130.662).

Competing interests

None declared.

Patient consent

Obtained.

Ethics approval

Medical Research Ethics Committee of the University Medical Center Utrecht.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data sharing statement

To promote the independent re-use of B-STARS data and to save the costs of unnecessarily compiling new datasets, access to a clean, anonymous, and well-annotated dataset will be made publicly available in a public


